Replimune Group Inc Quick Ratio (REPL) starting from the second quarter 2026 to second quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Replimune Group Inc   (NASDAQ: REPL)

Replimune Group Inc 's Quick Ratio

REPL's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Replimune Group Inc 's Cash & cash equivalent grew by 57.6 % in the Q2 2026 sequentially, faster than Current Liabilities, this led to improvement in Replimune Group Inc 's Quick Ratio to 5.57, Quick Ratio remained below Replimune Group Inc average.

Within Biotechnology & Pharmaceuticals industry 74 other companies have achieved higher Quick Ratio than Replimune Group Inc in second quarter 2026. While Quick Ratio total ranking in the second quarter 2026 has deteriorated compared to the prior quarter from 446 to 999.

Explain Quick Ratio?
How much Cash & cash equivalents REPL´s has?
What are REPL´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

REPL Quick Ratio (Sep 30 2026)
Q2		 (Jun 30 2026)
Q1		 (Mar 31 2026)
Q4		 (Dec 31 2025)
Q3		 (Sep 30 2025)
Q2
Y / Y Current Liabilities Change 4.48 % -28.2 % -56.32 % -1.92 % 20.8 %
Y / Y Cash & cash equivalent Change -4.89 % -51.57 % -44.42 % -49.84 % -25.09 %
Quick Ratio MRQ 5.57 4.57 9.87 4.32 6.12
REPL's Total Ranking # 999 # 446 # 354 # 469 #
Seq. Current Liabilities Change 29.24 % 57 % -56.25 % 17.71 % -11.19 %
Seq. Cash & cash equivalent Change 57.6 % -27.36 % -0.09 % -16.84 % -19.76 %



Quick Ratio second quarter 2026 Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 75
Healthcare Sector # 342
Overall Market # 999


Quick Ratio Statistics
High Average Low
32.74 15.64 4.57
(Dec 31 2021)   (Jun 30 2026)




Financial Statements
Replimune Group Inc 's Current Liabilities $ 55 Millions Visit REPL's Balance sheet
Replimune Group Inc 's Cash & cash equivalent $ 308 Millions Visit REPL's Balance sheet
Source of REPL's Sales Visit REPL's Sales by Geography


Cumulative Replimune Group Inc 's Quick Ratio

REPL's Quick Ratio for the trailling 12 Months

REPL Quick Ratio

 (Sep 30 2026)
12 Months		 (Jun 30 2026)
12 Months		 (Mar 31 2026)
12 Months		 (Dec 31 2025)
12 Months		 (Sep 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth -21.3 % -19.21 % -1.63 % 29.28 % 40.96 %
Y / Y Cash & cash equivalent TTM Growth -40.41 % -43.04 % -34.17 % -20.37 % -2.29 %
Quick Ratio TTM 5.55 5.71 6.26 6.24 7.33
Total Ranking TTM # 4358 # 4161 # 2065 # 2795 #
Seq. Current Liabilities TTM Growth 1.28 % -8.32 % -14.81 % -0.51 % 3.97 %
Seq. Cash & cash equivalent TTM Growth -1.5 % -16.44 % -14.52 % -15.3 % -5.84 %

Quick ratio ranking by company, industry and sector >> Back to REPL Financial Strength Comparisons >> Go to Compare REPL Quick Ratio to its Competitors

On the trailing twelve months basis Due to growth in Current Liabilities in the Q2 2026 to $55.27 millions, cumulative Quick Ratio decreased to 5.55 above the REPL average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry 155 other companies have achieved higher Quick Ratio than Replimune Group Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the first quarter 2026 from 4161 to 4358.

Explain Quick Ratio?
How much Cash & cash equivalents REPL´s has?
What are REPL´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Biotechnology & Pharmaceuticals Industry # 156
Healthcare Sector # 973
Within the Market # 4358


trailing twelve months Quick Ratio Statistics
High Average Low
11.81 4.75 1.78
(Dec 31 2021)   (Dec 31 2025)




Companies with similar Quick Ratio in the quarter ending Sep 30 2026, within Biotechnology & Pharmaceuticals Industry Quick RatioSep 30 2026 MRQ Cash & cash equivalentSep 30 2026 MRQ Current Liabilities
Vor Biopharma Inc   13.25 $ 481.551  Millions$ 36.344  Millions
Tectonic Therapeutic Inc   13.05 $ 234.666  Millions$ 17.986  Millions
Beam Therapeutics Inc   12.72 $ 1,043.873  Millions$ 82.076  Millions
X4 Pharmaceuticals Inc  12.53 $ 187.701  Millions$ 14.984  Millions
Odyssey Therapeutics, Inc.  12.49 $ 326.001  Millions$ 26.101  Millions
Solid Biosciences Inc   11.46 $ 348.928  Millions$ 30.454  Millions
Zura Bio Limited  9.22 $ 187.652  Millions$ 20.349  Millions
Protara Therapeutics Inc  8.83 $ 127.050  Millions$ 14.391  Millions
Repligen Corp  6.87 $ 862.979  Millions$ 125.686  Millions
Krystal Biotech Inc   6.45 $ 916.484  Millions$ 142.144  Millions
Voyager Therapeutics Inc   6.35 $ 106.806  Millions$ 16.813  Millions
Cabaletta Bio Inc   6.33 $ 299.383  Millions$ 47.332  Millions
Cognition Therapeutics inc   6.00 $ 30.758  Millions$ 5.128  Millions
Replimune Group Inc   5.57 $ 307.833  Millions$ 55.271  Millions
Denali Therapeutics Inc   5.42 $ 516.196  Millions$ 95.258  Millions
In8bio Inc   5.32 $ 13.973  Millions$ 2.628  Millions
Revolution Medicines Inc   4.81 $ 3,651.385  Millions$ 758.773  Millions
Caribou Biosciences Inc   4.71 $ 94.881  Millions$ 20.144  Millions
Recursion Pharmaceuticals Inc   4.47 $ 549.853  Millions$ 122.918  Millions
Fate Therapeutics Inc   4.26 $ 139.132  Millions$ 32.691  Millions
Kymera Therapeutics Inc   4.16 $ 373.374  Millions$ 89.723  Millions
Monte Rosa Therapeutics Inc   4.16 $ 577.726  Millions$ 139.022  Millions
Vir Biotechnology Inc   4.08 $ 454.635  Millions$ 111.332  Millions
Moderna Inc   3.93 $ 7,976.000  Millions$ 2,028.000  Millions
Immunocore Holdings Plc  3.93 $ 901.298  Millions$ 229.619  Millions
Alector Inc   3.92 $ 138.697  Millions$ 35.415  Millions
Dbv Technologies S a   3.89 $ 165.700  Millions$ 42.600  Millions
Regenxbio Inc   3.71 $ 250.976  Millions$ 67.684  Millions
Tenaya Therapeutics Inc   3.55 $ 66.797  Millions$ 18.804  Millions
Intensity Therapeutics Inc   3.29 $ 8.494  Millions$ 2.582  Millions

Date modified: 2026-10-29T10:08:34+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.